Iovance Biotherapeutics Inc

IOVA

$24.96

-23.2% (1 year change)

Market Cap

$3.97 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$15.88 - $54.21

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

0.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $3.97 Billion
Enterprise Value -
Dividend Yield $0.00 (0.0%)
1 Year Return -23.2%
52-Week High $54.21
52-Week Low $15.88
Beta 1.61
Outstanding Shares 155 Million
Avg 30 Day Volume 1.45 Million

Valuation

P/E Ratio 0.0
PEG -
Earnings per Share $0.00
Price to Sales Ratio -
Price to Book Ratio -
Revenue to Enterprise Value -
EBIT to Enterprise Value -
Total Debt to Enterprise Value -
Debt to Equity -

Profitability

Revenue -
Gross Profit -
EBIT -
Net Income -
Profit Margin -
Quarterly Earnings Growth (YoY) -
Return on Equity -
Return on Assets -
Return on Invested Capital -

News

Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 5, 2021

Iovance Biotherapeutics to Host Second Quarter Financial Results Conference Call and Webcast on Thursday, August 5, 2021

SAN CARLOS, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will rep...

Intrado Digital Media Intrado Digital Media, 2 months ago
NASDSQ:IOVA Shareholder Alert: Investigation Concerning Possible Wrongdoing at Iovance Biotherapeutics, Inc.

NASDSQ:IOVA Shareholder Alert: Investigation Concerning Possible Wrongdoing at Iovance Biotherapeutics, Inc.

An investigation on behalf of investors in Iovance Biotherapeutics, Inc. (NASDSQ:IOVA) shares over potential wrongdoing at Iovance Biotherapeutics, Inc. was announced. San Diego, CA -- ( SBWIRE ) -...

SBWire SBWire, 3 months ago
Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET

Iovance Biotherapeutics to Host Conference Call and Webcast to Discuss Clinical Data for LN-145 in Non-Small Cell Lung Cancer on June 29, 2021 at 4:30pm ET

SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announce...

Intrado Digital Media Intrado Digital Media, 3 months ago